Celon Pharma SA Total Liabilities
Celon Pharma SA total liabilities. Based on the latest financial reports, Celon Pharma SA (CLN) has total liabilities worth zł141.95 Million PLN (≈ $39.07 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Celon Pharma SA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Celon Pharma SA (2012–2025)
Total liabilities of Celon Pharma SA from 2012 to 2025. This chart illustrates how Celon Pharma SA's total liabilities have evolved over time, based on quarterly financial data. Check Celon Pharma SA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Celon Pharma SA Competitors by Total Liabilities
The table below lists competitors of Celon Pharma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
Korea | ₩954.63 Billion |
|
Kross Ltd
NSE:KROSS
|
India | Rs1.49 Billion |
|
Lemtech Holdings Co Ltd
TW:4912
|
Taiwan | NT$4.41 Billion |
|
SEACOR Marine Holdings Inc
NYSE:SMHI
|
USA | $392.91 Million |
|
GRM Overseas Limited
NSE:GRMOVER
|
India | Rs3.86 Billion |
|
Gersan Elektrik Ticaret ve Sanayi AS
IS:GEREL
|
Turkey | TL1.46 Billion |
|
Windlas Biotech Limited
NSE:WINDLAS
|
India | Rs2.80 Billion |
|
ARKO Petroleum Corp.
NASDAQ:APC
|
USA | $1.13 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Celon Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Celon Pharma SA asset portfolio.
Liquidity & Leverage Metrics
Celon Pharma SA Total Liabilities Ratios Explained
Celon Pharma SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celon Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celon Pharma SA (2012–2025)
The table below shows the annual total liabilities of Celon Pharma SA from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł74.47 Million ≈ $20.49 Million |
-24.47% |
| 2024-12-31 | zł98.59 Million ≈ $27.13 Million |
-20.33% |
| 2023-12-31 | zł123.75 Million ≈ $34.06 Million |
-4.28% |
| 2022-12-31 | zł129.29 Million ≈ $35.58 Million |
-15.57% |
| 2021-12-31 | zł153.14 Million ≈ $42.15 Million |
-43.07% |
| 2020-12-31 | zł268.97 Million ≈ $74.02 Million |
+83.84% |
| 2019-12-31 | zł146.31 Million ≈ $40.27 Million |
+27.29% |
| 2018-12-31 | zł114.94 Million ≈ $31.63 Million |
+34.90% |
| 2017-12-31 | zł85.20 Million ≈ $23.45 Million |
+37.82% |
| 2016-12-31 | zł61.82 Million ≈ $17.01 Million |
-8.38% |
| 2015-12-31 | zł67.47 Million ≈ $18.57 Million |
+88.38% |
| 2014-12-31 | zł35.82 Million ≈ $9.86 Million |
+17.86% |
| 2013-12-31 | zł30.39 Million ≈ $8.36 Million |
+113.63% |
| 2012-12-31 | zł14.22 Million ≈ $3.91 Million |
-- |
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.